drugset / Trial / NCT02171559

Relative Bioavailability and Pharmacodynamics of Dabigatran With Enoxaparin in Healthy Male and Female Volunteers

NCT02171559

Phase 1 Completed 29 enrolled Boehringer Ingelheim
RandomizedCrossoverOpen-labelTreatment

Summary

To investigate the relative bioavailability and the pharmacodynamics of dabigatran after switching from enoxaparin to dabigatran etexilate as compared to dabigatran etexilate alone

Timeline

Start
2008-08
Primary completion
2008-09
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Dabigatran etexilate Unknown 220 mg Oral
Subject Enoxaparin sodium Other / unclassified 40 mg Subcutaneous

Indications

No indication recorded.